Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) produce significantly greater weight loss (10-20%+) compared to other anti-obesity medications (3-7%) and placebo.
If lifestyle changes are not enough, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Mounjaro) offer the highest weight loss potential (10-20%). These are injectable medications typically used when BMI is >30 (or >27 with comorbidities). They work by reducing appetite and slowing digestion. Consult a physician to see if you qualify.
GLP- 1 receptor agonists semaglutide and tirzepatide appear to be significantly more efficient than other classes of medications. Semaglutide at 2.4 mg and tirzepatide at doses of 10 g and 15 mg can help patients reduce their body weight by more than 10%.
Why this rating
Based on large clinical trials (e.g., 803 participants for semaglutide, 2539 for tirzepatide) cited in the review.
Source
Review on obesity management: diet, exercise and pharmacotherapy
Katya Peri et al. · BMJ Public Health · 2024
DOI 10.1136/bmjph-2023-000246
More from this paper
- Combining a caloric deficit (500–750 kcal/day) with moderate-to-vigorous aerobic exercise (150–420 min/week) is significantly more effective for weight loss than either diet or exercise alone.Good
- Older pharmacotherapies (diethylpropion, orlistat, phentermine/topiramate) result in modest weight loss (3-7%) and are associated with significant side effects, making them less effective than newer GLP-1 agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →